Related Experiment Videos
SRPK1: a cisplatin sensitive protein expressed in retinoblastoma
Subramanian Krishnakumar1, Adithi Mohan, Mallikarjuna Kandalam
1Department of Ocular Pathology, Vision Research Foundation, Chennai, Tamil Nadu, India. drkrishnakumar_2000@yahoo.com
Abstract:
Chemotherapy is an essential modality in the treatment of retinoblastoma (RB). Mammalian serine/arginine-rich protein-specific kinase 1 (SRPK1) is a cisplatin-sensitivity-related protein and its downregulation is known to be associated with decreased response to cisplatin and carboplatin. We investigated the expression of SRPK1 in 63 archival RB and correlated its expression with pathologic staging and exposure to chemotherapy. The majority of the RB (62/63) were advanced stage (Groups D and E) with intermediate to high risk of treatment failure according to the new international classification for intraocular RB and SRPK1 was reduced in 32/62 (51%) tumors. SRPK1 protein expression was reduced in (100%) 8/8 RB that had recurred in the orbit or had metastasized. SRPK1 protein expression is reduced in RB with advanced stage of presentation and this may add to drug resistance mechanisms in RB.
Insights
Reduced serine/arginine-rich protein-specific kinase 1 (SRPK1) expression in retinoblastoma (RB) tumors correlates with advanced stages and metastasis. This finding suggests SRPK1 may play a role in chemotherapy resistance in RB.
Area of Science:
- Oncology
- Molecular Biology
- Ophthalmology
Background:
- Chemotherapy is a critical treatment for retinoblastoma (RB).
- Serine/arginine-rich protein-specific kinase 1 (SRPK1) influences sensitivity to cisplatin and carboplatin.
- Downregulation of SRPK1 is linked to reduced chemotherapy response.
Purpose of the Study:
- To investigate SRPK1 expression in retinoblastoma tumors.
- To correlate SRPK1 levels with pathological staging and chemotherapy exposure.
- To explore SRPK1's potential role in RB drug resistance.
Main Methods:
- Analysis of SRPK1 expression in 63 archival retinoblastoma (RB) samples.
- Correlation of SRPK1 levels with international retinoblastoma staging (Groups D and E).
- Assessment of SRPK1 expression in recurrent or metastatic RB cases.
Main Results:
- SRPK1 was reduced in 51% (32/62) of advanced-stage RB tumors.
- All cases (8/8) of recurrent or metastatic RB showed reduced SRPK1 protein expression.
- Reduced SRPK1 expression was observed in advanced-stage retinoblastoma.
Conclusions:
- SRPK1 protein expression is decreased in advanced-stage retinoblastoma.
- Reduced SRPK1 may contribute to chemotherapy resistance mechanisms in RB.
- Further research into SRPK1's role in RB treatment is warranted.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Negative Regulator Molecules
The Ras Gene
Ras is a superfamily...